EICHORCondition: Advanced Solid Tumours · Sponsor: LaNova Medicines Limited
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
For phase I ,this study is to assess the safety and tolerability, obtain the recommended phase 2 dose (RP2D) and/or Maximum Tolerated Dose (MTD) for LM-168 as a single agent or in combination with toripalimab in subjects with advanced solid tumours. For phase II ,this study is to assess the preliminary anti-tumour activity of LM-168 as a single agent or in combination with toripalimab measured by objective response rate (ORR) in subjects with advanced solid tumours.
This description comes directly from the study's public registry record.
Alex Yuan · +8615901815211 · alexyuan@lanovamed.com
Paul Kong · +8613564682439 · paulkong@lanovamed.com
Always discuss trial participation with your own doctor first.
| Macquarie University | Ryde, New South Wales, Australia | Recruiting |
| MUPharm Pty Limited trading as Macquarie University Hospital Parmarcy | Ryde, New South Wales, Australia | Recruiting |
| Cancer Care Wollongong Pty Limited | Wollongong, New South Wales, Australia | Recruiting |
| Bayview Health-Investigational Drug Services | Perth, Western Australia, Australia | Recruiting |
| One Clinical Reasearch | Perth, Western Australia, Australia | Recruiting |
| Beijing Cancer Hospital | Beijing, Beijing Municipality, China | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06868199